The history of RAC is certainly being "exciting", but the direction and focus has remained consistent since the end of 2023. We have delivered on the GMP development of RC220, it has passed all the GLP studies, the SP has recovered from the 2023 lows, additional capital was raised successfully, the board rebuilt, and the ethics (and all the other associated) documentation delivered on time and submitted. The only thing on the critical path that wasn't accomplished to schedule was submission of the ethics application by the end of September, but it was submitted at the beginning of December.
I am very biased, but when I look back at the path and timeline laid out in November 2023 I am very happy that so much has gone exactly to plan. This is not easy in the biotech space (especially on a tight budget) and is a real credit to the team at Race and all our external consultants.
RAC Price at posting:
$1.30 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)